P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells

Experimental Cell Research

Volumn 317, Issue 12, 2011, Pages 1736-1745

  Chapman, Jacqueline V ^a   Gouazé Andersson, Valérie ^a   Karimi, Ramin ^a   Messner, Maria C ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

C6 ceramide; Ceramide; Drug resistance; Ovarian cancer; P glycoprotein; P glycoprotein antagonists

Indexed keywords

BIRICODAR; CASPASE 3; CASPASE 7; CERAMIDE; CYCLOSPORIN; GLUCOSYLCERAMIDE; GLYCOPROTEIN P; TAMOXIFEN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 79958838496     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.03.004     Document Type: Article

References (74)

1. Abe A., Wu D., Shayman J.A., Radin N.S. Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C. Eur. J. Biochem. 1992, 210:765-773.
2. Modrak D.E., Gold D.V., Goldenberg D.M. Sphingolipid targets in cancer therapy. Mol. Cancer Ther. 2006, 5:200-208.
3. Eckford P.D., Sharom F.J. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem. J. 2005, 389:517-526.
4. Borst P., Zelcer N., van Helvoort A. ABC transporters in lipid transport. Biochim. Biophys. Acta 2000, 1486:128-144.
5. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87:507-517.
6. De Rosa M.F., Sillence D., Ackerley C., Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 2004, 279:7867-7876.
7. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
8. Sikic B.I. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park) 1999, 13:183-187.
9. Bradley G., Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 1994, 13:223-233.
10. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
11. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
12. Krishnamurthy P., Schuetz J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 2006, 46:381-410.
13. Yang K., Wu J., Li X. Recent advances in the research of P-glycoprotein inhibitors. Biosci. Trends 2008, 2:137-146.
14. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7:861-879.
15. Baumert C., Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med. Chem. 2009, 9:415-436.
16. Fracasso P.M., Brady M.F., Moore D.H., Walker J.L., Rose P.G., Letvak L., Grogan T.M., McGuire W.P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2001, 19:2975-2982.
17. Baekelandt M., Lehne G., Trope C.G., Szanto I., Pfeiffer P., Gustavssson B., Kristensen G.B. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J. Clin. Oncol. 2001, 19:2983-2993.
18. Lhomme C., Joly F., Walker J.L., Lissoni A.A., Nicoletto M.O., Manikhas G.M., Baekelandt M.M., Gordon A.N., Fracasso P.M., Mietlowski W.L., Jones G.J., Dugan M.H. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 2008, 26:2674-2682.
19. Hall M.D., Handley M.D., Gottesman M.M. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 2009, 30:546-556.
20. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V., Rossi Degl'innocenti D., Taddei G.L. Microvessel density in ovarian carcinoma: computer image analysis in patients with shorter and longer survival. Int. J. Gynecol. Cancer 2005, 15:844-849.
21. Penson R.T., Oliva E., Skates S.J., Glyptis T., Fuller A.F., Goodman A., Seiden M.V. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol. Oncol. 2004, 93:98-106.
22. Baekelandt M.M., Holm R., Nesland J.M., Trope C.G., Kristensen G.B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000, 20:1061-1067.
23. Green H., Soderkvist P., Rosenberg P., Horvath G., Peterson C. ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J. Pharm. Sci. 2008, 97:2045-2048.
24. Yakirevich E., Sabo E., Naroditsky I., Sova Y., Lavie O., Resnick M.B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006, 100:152-159.
25. Krasznai Z.T., Friedlander E., Nagy A., Szabo G., Vereb G., Goda K., Hernadi Z. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer. Anticancer Res. 2005, 25:1187-1192.
26. Hendrick A.M., Harris A.L., Cantwell B.M. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann. Oncol. 1991, 2:71-72.
27. Morgan R.J., Synold T.W., Gandara D., Muggia F., Scudder S., Reed E., Margolin K., Raschko J., Leong L., Shibata S., Tetef M., Vasilev S., McGonigle K., Longmate J., Yen Y., Chow W., Somlo G., Carroll M., Doroshow J.H. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother. Pharmacol. 2004, 54:283-289.
28. Apoptosis, Senescence, and Cancer 2007, Humana Press Inc., Totowa, NJ. D.A. Gewirtz, S.E. Holt, S. Grant (Eds.).
29. Fracasso P.M. Overcoming drug resistance in ovarian carcinoma. Curr. Oncol. Rep. 2001, 3:19-26.
30. Radin N.S. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem. J. 2003, 371:243-256.
31. Ruvolo P.P. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 2003, 47:383-392.
32. Hannun Y.A., Luberto C., Argraves K.M. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 2001, 40:4893-4903.
33. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J. Natl Cancer Inst. 2001, 93:347-357.
34. Kolesnick R., Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
35. Charles A.G., Han T.Y., Liu Y.Y., Hansen N., Giuliano A.E., Cabot M.C. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother. Pharmacol. 2001, 47:444-450.
36. Maurer B.J., Melton L., Billups C., Cabot M.C., Reynolds C.P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl Cancer Inst. 2000, 92:1897-1909.
37. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. 1999, 274:1140-1146.
38. Liu Y.Y., Han T.Y., Giuliano A.E., Hansen N., Cabot M.C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 2000, 275:7138-7143.
39. Lavie Y., Cao H., Volner A., Lucci A., Han T.Y., Geffen V., Giuliano A.E., Cabot M.C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem. 1997, 272:1682-1687.
40. Lee L., Abe A., Shayman J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 1999, 274:14662-14669.
41. Liu Y.Y., Yu J.Y., Yin D., Patwardhan G.A., Gupta V., Hirabayashi Y., Holleran W.M., Giuliano A.E., Jazwinski S.M., Gouaze-Andersson V., Consoli D.P., Cabot M.C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008, 22:2541-2551.
42. Gouaze V., Liu Y.Y., Prickett C.S., Yu J.Y., Giuliano A.E., Cabot M.C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 2005, 65:3861-3867.
43. Shukla G.S., Radin N.S. Glucosyceramide synthase of mouse kidney: further characterization with an improved assay method. Arch. Biochem. Biophys. 1990, 283:372-378.
44. Gouaze V., Yu J.Y., Bleicher R.J., Han T.Y., Liu Y.Y., Wang H., Gottesman M.M., Bitterman A., Giuliano A.E., Cabot M.C. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 2004, 3:633-639.
45. Gouaze-Andersson V., Yu J.Y., Kreitenberg A.J., Bielawska A., Giuliano A.E., Cabot M.C. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim. Biophys. Acta 2007, 1771:1407-1417.
46. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
47. Callaghan R., Higgins C.F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer 1995, 71:294-299.
48. Cabot M.C., Giuliano A.E., Volner A., Han T.Y. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett. 1996, 394:129-131.
49. Cabot M. Ceramide glycosylation and chemotherapy resistance. Ceramide Signaling 2002, vol. 21:133-139. Landes Bioscience, Georgetown, Texas. A.H. Futerman (Ed.).
50. Sietsma H., Veldman R.J., Kolk D., Ausema B., Nijhof W., Kamps W., Vellenga E., Kok J.W. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res. 2000, 6:942-948.
51. Auzenne E., Leroux M.E., Hu M., Pollock R.E., Feig B., Klostergaard J. Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro. Melanoma Res. 1998, 8:227-239.
52. Fillet M., Bentires-Alj M., Deregowski V., Greimers R., Gielen J., Piette J., Bours V., Merville M.P. Mechanisms involved in exogenous C2- and C6-ceramide-induced cancer cell toxicity. Biochem. Pharmacol. 2003, 65:1633-1642.
53. Takeda S., Mitsutake S., Tsuji K., Igarashi Y. Apoptosis occurs via the ceramide recycling pathway in human HaCaT keratinocytes. J. Biochem. 2006, 139:255-262.
54. Ogretmen B., Pettus B.J., Rossi M.J., Wood R., Usta J., Szulc Z., Bielawska A., Obeid L.M., Hannun Y.A. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J. Biol. Chem. 2002, 277:12960-12969.
55. Minderman H., O'Loughlin K.L., Pendyala L., Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 2004, 10:1826-1834.
56. Germann U.A., Shlyakhter D., Mason V.S., Zelle R.E., Duffy J.P., Galullo V., Armistead D.M., Saunders J.O., Boger J., Harding M.W. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997, 8:125-140.
57. Liscovitch M., Ravid D. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett. 2007, 245:350-352.
58. Tran M.A., Smith C.D., Kester M., Robertson G.P. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res. 2008, 14:3571-3581.
59. Stover T.C., Kim Y.S., Lowe T.L., Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 2008, 29:359-369.
60. Bleicher R.J., Cabot M.C. Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta 2002, 1585:172-178.
61. Lucci A., Giuliano A.E., Han T.Y., Dinur T., Liu Y.Y., Senchenkov A., Cabot M.C. Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int. J. Oncol. 1999, 15:535-540.
62. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., Cabot M.C. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int. J. Oncol. 1999, 15:541-546.
63. Shabbits J.A., Mayer L.D. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther. 2002, 1:205-213.
64. Lavie Y., Cao H., Bursten S.L., Giuliano A.E., Cabot M.C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem. 1996, 271:19530-19536.
65. Lucci A., Cho W.I., Han T.Y., Giuliano A.E., Morton D.L., Cabot M.C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res. 1998, 18:475-480.
66. Veldman R.J., Klappe K., Hinrichs J., Hummel I., van der Schaaf G., Sietsma H., Kok J.W. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J. 2002, 16:1111-1113.
67. Lala P., Ito S., Lingwood C.A. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis. J. Biol. Chem. 2000, 275:6246-6251.
68. Molinari A., Calcabrini A., Meschini S., Stringaro A., Crateri P., Toccacieli L., Marra M., Colone M., Cianfriglia M., Arancia G. Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr. Protein Pept. Sci. 2002, 3:653-670.
69. Kirk J., Houlbrook S., Stuart N.S., Stratford I.J., Harris A.L., Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur. J. Cancer 1993, 29A:1152-1157.
70. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz-Friedman A., Fuks Z., Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380:75-79.
71. Nica A.F., Tsao C.C., Watt J.C., Jiffar T., Kurinna S., Jurasz P., Konopleva M., Andreeff M., Radomski M.W., Ruvolo P.P. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle 2008, 7:3362-3370.
72. Mabuchi S., Ohmichi M., Kimura A., Ikebuchi Y., Hisamoto K., Arimoto-Ishida E., Nishio Y., Takahashi K., Tasaka K., Murata Y. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004, 145:1302-1313.
73. Cabot M.C., Zhang Z., Cao H., Lavie Y., Giuliano A.E., Han T.Y., Jones R.C. Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int. J. Cancer 1997, 70:567-574.
74. Mandlekar S., Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477.